<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-id journal-id-type="hwp">ofids</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26949713</article-id><article-id pub-id-type="pmc">4758327</article-id><article-id pub-id-type="doi">10.1093/ofid/ofv183</article-id><article-id pub-id-type="publisher-id">ofv183</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial</article-title></title-group><pub-date pub-type="collection"><month>1</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>18</day><month>2</month><year>2016</year></pub-date><volume>3</volume><issue>1</issue><elocation-id>ofv183</elocation-id><permissions><copyright-statement>&#x000a9; The Author 2016. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.</copyright-statement><copyright-year>2016</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="ofv183.pdf"/><counts><page-count count="1"/></counts><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>Winter 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>&#x0201c;Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial&#x0201d; by Edgar Turner Overton et al (<related-article id="d36e72" related-article-type="corrected-article" ext-link-type="doi" xlink:href="10.1093/ofid/ofv040">Spring <bold>2015</bold> 2(2): doi:10.1093/ofid/ofv040</related-article>) did not include author Josef Weigl as the 10th author and omitted his affiliation with the Public Health Institute Ploen, Hamburgerstr, Germany in the final version of the manuscript.</p><p>The corresponding author regrets this omission.</p></body></article>